Get the Daily Brief
Latest Biotech News
ARPA‑H awards flow: Tempus and Tessera win major program funding
Tempus AI was awarded a $60.5 million five‑year contract by ARPA‑H to provide testing and CRO services for the ADAPT precision cancer therapy program, supplying whole transcriptome, exome, liquid...
Evommune files for IPO — funding late‑stage autoimmune trials
Evommune filed confidentially to go public to raise capital for two mid‑stage programs: EVO756, an oral MRGPRX2 antagonist for chronic spontaneous urticaria and atopic dermatitis, and EVO301, an...
Gene therapy momentum: Sarepta files for LGMD approval; Chiesi funds Arbor CRISPR pact
Sarepta Therapeutics reported data showing its experimental gene therapy raised levels of the missing protein in limb‑girdle muscular dystrophy (LGMD) 2E and said it will seek regulatory...
Novo buys Akero for $4.7B — bolsters MASH pipeline
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion in cash, taking ownership of Akero’s late‑stage FGF21 analogue efruxifermin and related assets. The deal includes contingent...
Bristol Myers to buy Orbital for $1.5B — deepens in vivo CAR‑T push
Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion in cash to add Orbital’s in vivo CAR‑T platform and preclinical CD19 autoimmune programs to its pipeline. The deal expands...
ARPA‑H funds Tessera’s in vivo CAR‑T work — up to $41.3M award
Tessera Therapeutics has been awarded up to $41.3 million from ARPA‑H to support its EMBODY program aimed at engineering immune cells directly inside the body. The funding will accelerate...
Chiesi inks Arbor alliance — $115M to back in vivo CRISPR for rare liver disease
Chiesi Global Rare Diseases committed up to $115 million to partner with Arbor Biotechnologies on an in vivo CRISPR gene‑editing candidate for primary hyperoxaluria type 1 (PH1) and other liver...
Mammoth prepares first trial — gene edit to lower triglycerides shows monkey data
Mammoth Biosciences disclosed preclinical nonhuman primate data for its lead in vivo gene‑editing program intended to permanently lower triglycerides and announced plans for a first clinical...
Pig‑to‑human auxiliary liver transplant — graft supported metabolism 38 days
Surgeons in China transplanted a genetically modified pig liver segment into a patient with cancer as an auxiliary graft; the xenograft supported metabolic function for 38 days before being...
Senate passes new Biosecure Act amendment — tighter US biotech ties to China loom
The U.S. Senate passed a revised version of the Biosecure Act as an amendment to the FY26 National Defense Authorization Act, seeking to restrict federal contracts and funding with biotechnology...
Illumina alliance tops 250K genomes — pharma partners ramp access to diverse cohorts
Illumina’s Alliance for Genomic Discovery has now sequenced over 250,000 genomes from the Vanderbilt BioVU biobank and added pharmaceutical partners including Alnylam, expanding industry access to...
Tempus wins $60.5M ARPA‑H contract — to power precision cancer ADAPT program
Tempus AI secured a $60.5 million, five‑year contract from ARPA‑H to provide sequencing, diagnostic assays and contract research services for the ADAPT precision cancer therapy initiative. The...
Epigenetic editor silences PCSK9 — durable LDL reductions seen in primates
Researchers reported that an mRNA‑delivered epigenetic editing therapy, dubbed Epi‑Reg, achieved long‑lasting reductions in PCSK9 expression and LDL cholesterol in human cells, mice and nonhuman...
Novo buys Akero for $4.7B — stakes claim in MASH drug class
Novo Nordisk agreed to acquire Akero Therapeutics for $4.7 billion in cash, securing efruxifermin, an FGF21 analogue in late‑stage testing for metabolic dysfunction‑associated steatohepatitis...
Bristol Myers spends $1.5B to join in vivo CAR‑T race
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash, bringing Orbital’s in vivo CAR‑T technology into BMS’s cell‑therapy portfolio. The acquisition is the latest...
Senate advances Biosecure Act — federal biotech ties face new limits
The U.S. Senate passed a revised iteration of the Biosecure Act as an amendment to the National Defense Authorization Act, proposing restrictions on federal funding and contracting with...
Biopharma doubles down on in vivo CAR‑T: deals and awards pile up
Commercial and public funders are accelerating investment in in vivo CAR‑T approaches as early human data and enabling delivery technologies surface. Industry players have spent billions buying...
Epigenetic editing lowers LDL in primates — single dose durability
Researchers delivered an mRNA‑based epigenetic editor targeting PCSK9 that produced durable LDL cholesterol reductions in nonhuman primates for nearly a year after a single dose. The team reported...
Pan‑disease blood proteome: 9K samples map 59 illnesses — biomarker atlas
An international consortium led by KTH SciLifeLab and collaborators published a pan‑disease blood proteome that profiles protein changes across 59 diseases using Olink’s high‑throughput panels and...
Judge invalidates Scale patent — Parse Bio scores legal win
A U.S. district court found key claims of a Scale Biosciences patent invalid for inadequate written description and enablement, handing Parse Biosciences a win in an ongoing infringement dispute....